Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accounts Payables (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Accounts Payables for 4 consecutive years, with $8.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 79.4% to $8.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.5 million, a 79.4% increase, with the full-year FY2024 number at $5.1 million, up 77.03% from a year prior.
  • Accounts Payables was $8.5 million for Q3 2025 at Orchestra BioMed Holdings, up from $5.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $8.5 million in Q3 2025 to a low of $103607.0 in Q1 2022.
  • A 4-year average of $3.7 million and a median of $3.4 million in 2024 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 2568.74% in 2023; the steepest drop was 26.92% in 2023.
  • Orchestra BioMed Holdings' Accounts Payables stood at $4.0 million in 2022, then fell by 26.92% to $2.9 million in 2023, then surged by 77.03% to $5.1 million in 2024, then soared by 65.04% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Accounts Payables are $8.5 million (Q3 2025), $5.3 million (Q2 2025), and $5.6 million (Q1 2025).